Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-04-16 Capital/Financing Update
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Neurotech Completes $10 Million Capital Raise 3 pages 204.1KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 17 April 2024, titled 'Neurotech Completes $10.0 Million Capital Raise'. It details the completion of a $10 million placement of new shares and options, including the issue price, discount to market price, and use of funds. The content focuses on the capital raising event, investor participation, and intended use of proceeds for clinical trials and manufacturing expansion. There is no detailed financial report, earnings data, or management discussion of financial results. The document is not a full annual or interim report, nor is it a regulatory certification or voting result. It clearly fits the category of a capital/financing update as it announces a fundraising event and related share issuance. The document length (8797 characters) and content confirm it is a full announcement rather than a brief notice or report publication announcement.
2024-04-16 English
Proposed issue of securities - NTI 6 pages 21.7KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed placement of securities by Neurotech International Limited. It includes specifics such as the number and type of securities to be issued, issue price, proposed issue date, conditions, fees, and purpose of the capital raise. The document is a formal announcement related to the company's capital raising activities and securities issuance, consistent with ASX Listing Rules requirements. There is no financial performance data, earnings information, or management discussion, nor is it a report or transcript. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2024-04-16 English
Investor Presentation 35 pages 2.5MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation' and contains detailed information about clinical trial results, capital raise, market analysis, and program highlights. It includes forward-looking statements, disclaimers about investment advice, and detailed data on clinical trials and patient characteristics. The content is typical of a presentation aimed at investors, focusing on financial and strategic information rather than a formal regulatory filing or financial report. There is no indication that this is an official annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content support it being a full investor presentation rather than a brief announcement or summary. Therefore, the document fits the category of an Investor Presentation (IP).
2024-04-16 English
Investor Webinar on Clinical Trial Results 1 page 1
Investor Presentation Classification · 80% confidence The document is an ASX announcement dated 16 April 2024, announcing an upcoming investor webinar to discuss clinical trial results. It includes details about the webinar timing, registration link, and contact information. There is no detailed financial data, no full report, and no regulatory filing of financial results. The document is essentially an announcement of an investor presentation event rather than the presentation itself or a financial report. Given the content and purpose, the most appropriate classification is Investor Presentation (IP). However, since the document is announcing the webinar rather than providing the presentation content, it could be considered a Regulatory Filing (RNS) as a general announcement. But the document is focused on the investor presentation event, so IP is more fitting. The document length is short (2536 characters), and it does not contain actual financial statements or detailed analysis, so it is not an Interim Report or Annual Report. Therefore, the best fit is Investor Presentation (IP) with moderate confidence due to the announcement nature.
2024-04-15 English
Trading Halt 2 pages 148.6KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited regarding a request for a trading halt on its securities. It references pending announcements about clinical trial results and a capital raising but does not contain any financial data, detailed report, or results itself. The document is short (2301 characters) and serves as a notification to the market about the trading halt, not the actual report or announcement of results. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit into more specific categories.
2024-04-14 English
Last Patient Completes Treatment in NTIASD2 Clinical Trial 3 pages 192.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 April 2024 from Neurotech International Limited. It announces the completion of the last patient treatment in a Phase II/III clinical trial for Autism Spectrum Disorder (ASD). The content focuses on clinical trial progress, patient recruitment, trial design, and expected results timing. There are no financial statements, earnings data, or detailed financial analysis. The document is a progress update on clinical trial milestones rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial completion, not just a notice of report availability. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress that does not fit into other specific categories such as earnings release, capital update, or management information.
2024-04-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.